In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor

Yu, Y; Hall, T; Eathiraj, S; Wick, MJ; Schwartz, B; Abbadessa, G

Yu, Y (reprint author), ArQule Inc, One Wall St, Burlington, MA 01803 USA.

ANTI-CANCER DRUGS, 2017; 28 (5): 503

Abstract

The PI3K/AKT pathway plays an important role in the initiation and progression of cancer, and the drug development efforts targeting this pathway with......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索